The clinical relevance of recent developments in pathology and biology of small cell lung cancer.

characterized by early and wide dissemination and with a great sensitivity to both chemotherapy and radiotherapy. Despite the objective response to chemotherapy in more than 85%, most of the patients sooner or later develop clinical relapse, and fewer than 10% become long-term survivors. The need is thus urgent for more biologic knowledge about this disease, and great efforts have been put into this field of research by scientists all over the world. Through detailed studies, especially on more than 100 established cell lines from SCLC, much biologic information has been accumulated including the relationship of SCLC to both other histologic types of lung cancers and to endocrine tumors. The present short overview deals with the clinical significance of recent scientific developments in the histopathologic and biologic studies of SCLC.

[1]  R. Makuch,et al.  myc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines. , 1988, Cancer research.

[2]  R. Steele,et al.  Histopathologic classification of small cell lung cancer changing concepts and terminology , 1988, Cancer.

[3]  B. Wiedenmann,et al.  Expression of neuroendocrine markers (neuronspecific enolase, synaptophysin and bombesin) in carcinoma of the lung. , 1988, Pathology, research and practice.

[4]  R. Stahel,et al.  Chapter 6 Reactivity of SCLC associated monoclonals SWA4, SWA20 & SWA23 in formalin paraffin sections , 1988 .

[5]  I. Smith,et al.  Somatomedin-C/insulin-like growth factor-I is a mitogen for human small cell lung cancer. , 1988, British Journal of Cancer.

[6]  J. Osinga,et al.  Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer , 1987, Nature.

[7]  G. Bepler,et al.  Amplification and expression of protooncogenes in human small cell lung cancer cell lines. , 1987, Cancer research.

[8]  K. Fujita,et al.  Evaluation of γ‐enolase as a tumor marker for lung cancer , 1987 .

[9]  U. Novak,et al.  Heterogeneous cytogenetic abnormalities in small cell lung cancer cell lines. , 1987, Cancer research.

[10]  R. Makuch,et al.  myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. , 1987, The Journal of clinical investigation.

[11]  J. Catino,et al.  Small cell lung cancer cell line derived from a primary tumor with a characteristic deletion of 3p. , 1987, Cancer research.

[12]  D. Carney.  Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide , 1987, Regulatory Peptides.

[13]  R. B. Wuerker,et al.  Relationship between changes in the histologic subtype of small cell carcinoma of the lung and the response to chemotherapy. , 1986, American journal of clinical oncology.

[14]  S. Baylin,et al.  Gene amplification of c-myc and N-myc in small cell carcinoma of the lung. , 1986, Science.

[15]  R. Stahel,et al.  Cytotoxic murine monoclonal antibody LAM8 with specificity for human small cell carcinoma of the lung. , 1986, Cancer research.

[16]  F. Hirsch,et al.  Morphologic variations of small cell lung cancer: A histopathologic study of pretreatment and posttreatment specimens in 104 patients , 1986, Cancer.

[17]  J. Battey,et al.  Human small-cell lung cancers show amplification and expression of the N-myc gene. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Battey,et al.  L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer , 1985, Nature.

[19]  J. Bergh,et al.  Immunocytochemical demonstration of neuron-specific enolase (NSE) in human lung cancers. , 1985, American journal of clinical pathology.

[20]  J. Minna,et al.  Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. , 1985, Cancer research.

[21]  B. Corrin,et al.  Neural markers in carcinoma of the lung. , 1985, British Journal of Cancer.

[22]  J. Bergh,et al.  Amplification of the c-myc oncogene in a subpopulation of human small cell lung cancer. , 1985, Cancer research.

[23]  R. Stahel,et al.  Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Minna,et al.  Small cell lung cancer, endocrine cells of the fetal bronchus, and other neuroendocrine cells express the Leu-7 antigenic determinant present on natural killer cells. , 1985, Blood.

[25]  R. Lloyd,et al.  Immunoreactive neuron-specific enolase, bombesin, and chromogranin as markers for neuroendocrine lung tumors. , 1985, Human pathology.

[26]  A. Dhillon,et al.  PGP 9.5, a new marker for human neuroendocrine tumours , 1985, Histopathology.

[27]  D. Bostwick,et al.  Gastrin-releasing peptide, a mammalian analog of bombesin, is present in human neuroendocrine lung tumors. , 1984, The American journal of pathology.

[28]  C. Pert,et al.  Small cell carcinoma of the lung: macrophage-specific antigens suggest hemopoietic stem cell origin. , 1984, Science.

[29]  R. Lloyd,et al.  Detection of chromogranin in neuroendocrine cells with a monoclonal antibody. , 1984, The American journal of pathology.

[30]  F. Hirsch,et al.  The prognostic significance of histopathologic subtyping of small cell carcinoma of the lung according to the classification of the world health organization. A study of 375 consecutive patients , 1983, Cancer.

[31]  J. Minna,et al.  Amplification and expression of the c-myc oncogene in human lung cancer cell lines , 1983, Nature.

[32]  R. Makuch,et al.  The clinical behavior of „mixed”︁ small cell/large cell bronchogenic carcinoma compared to „pure”︁ small cell subtypes , 1982, Cancer.

[33]  F. Hirsch,et al.  Histopathologic classification of small cell carcinoma of the lung. Comments based on an interobserver examination , 1982, Cancer.

[34]  D. Ettinger,et al.  Changes in morphologic and biochemical characteristics of small cell carcinoma of the lung. A clinicopathologic study. , 1979, The American journal of medicine.

[35]  N. Bleehen,et al.  Growth inhibition by neurotensin in small cell lung cancer cell lines in vitro , 1988 .

[36]  J. Minna,et al.  Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer , 1987, Nature.

[37]  P. Postmus,et al.  The Use of Monoclonal Antibodies for the Pathological Diagnosis of Lung Cancer , 1986 .

[38]  John D. Minna,et al.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer , 1985, Nature.

[39]  O. Auerbach.  Histological Typing Of Lung Tumors , 1968 .